Skip to content

    Rubicon Research Q1 FY27 earnings call

    RUBICON
    Healthcare·14 Aug 2026
    Management Summary

    Rubicon Research Limited delivered a strong Q1 FY27, marked by significant year-on-year growth in revenue, EBITDA, and PAT, driven by a diversified product portfolio and strategic focus on specialty products. The company successfully navigated FDA inspections for its Pithampur and newly acquired New Jersey facilities, paving the way for future commercialization. Despite temporary cash flow impacts from delayed GST refunds and a strategic shedding of lower-margin USD business, management expressed confidence by revising its FY27 EBITDA guidance upwards, reflecting robust operational efficiency and R&D productivity.

    Highlights

    5
    • Revenue from operations grew 51% YoY to INR534.3 crores, demonstrating strong top-line performance.

    • Operating EBITDA increased by 63.2% YoY to INR129.1 crores, with margin expanding to 24.2% from 22.4% in Q1 previous year.

    • PAT surged 96% YoY to INR84.8 crores, resulting in an EPS of INR5.08.

    • R&D productivity (incremental revenue to lagging R&D spend) stands at an impressive 5.5x, with expectations for further expansion.

    • Management revised its full-year FY27 EBITDA guidance upwards from the previous 22-23% range, indicating confidence in sustained profitability.

    Concerns

    3
    • Net cash flow from operating activity was INR28.5 crores, impacted by delays in GST refunds, though normalization is expected in Q2 FY27.

    • A slight sequential drop in USD revenues was noted due to tactical measures to shed lower-margin businesses, impacting top-line growth in that segment.

    • The reported PAT of INR84.8 crores includes a one-off insurance claim, though core PAT growth remained strong at 96% YoY.

    Key financials

    Single quarter

    11 metrics
    1. 01Revenue from Operations₹534.3 Cr+51%YoY
    2. 02Gross Profit₹354.3 Cr+46%YoY
    3. 03Pre-R&D EBITDA₹187.1 Cr
    4. 04Pre-R&D EBITDA Margin35%
    5. 05R&D Expense₹58 Cr

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    M&A

    Arinna Lifesciences

    acquisition · closed

    M&A

    Manufacturing site in New Jersey, USA

    acquisition · closed · Consideration USD 2.9 million

    Liquidity

    Cash ₹240.8 crores

    Net cash flow from operating activity was INR28.5 crores, impacted by delayed GST refunds, expected to normalize in Q2.

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    Upwards of 22-23%
    High
    R&D
    R&D Spend
    INR500 crores
    High
    Capacity
    Pithampur Commercial Operations
    Ramp up from Q1 CY27
    High
    Capacity
    New Jersey Commercial Operations
    Start in CY27
    High
    Working Capital
    Net Working Capital Days
    125-130 days
    Medium

    What to watch in Q2 FY27

    5

    Normalization of cash flow from operations

    Q2 FY27
    CurrentINR28.5 crores (impacted by delayed GST refunds)
    TargetImproved cash flow from operations

    Why it matters

    Indicates operational efficiency and effective working capital management, crucial for funding growth.

    In this quarter, the cash flow was impacted because of some delay in GST refunds and these refunds are getting normalized and we should see the impact of this in Q2 in terms of healthy cash flow for the quarter.

    Risks & concerns

    3
    RiskSeverity

    Delay in GST refunds impacting cash flow

    Net cash flow from operating activity was INR28.5 crores, impacted by delayed GST refunds, but expected to normalize in Q2.Management acknowledged

    medium

    Increased input and freight costs due to geopolitical conditions

    Gross margin increased despite sequential increase in key input and freight costs, managed through tactical measures.Management acknowledged

    medium

    Potential US tariffs impacting exports

    Analyst raised concern about potential US tariffs given 97% export to US, but management did not directly address the tariff impact.Analyst not addressed

    low

    Q&A highlights

    8

    “So as we mentioned earlier that our portfolio is pretty broad-based. If you look at the concentration of top 5, top 10 products over the years have continued to come down even if you look at last few quarters, it's range-bound. Okay. So that's the point, it's a fairly broad-based portfolio, continues to grow.”

    Reassures investors about diversified growth and reduced reliance on a few products, indicating sustained demand across the portfolio.

    asked by Akshay

    3 min read7 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Financial Performance

    Rubicon Research reported robust financial results for Q1 FY27, with revenue from operations reaching INR534.3 crores, marking a 51% year-on-year growth. Operating EBITDA surged by 63.2% to INR129.1 crores, expanding the margin to 24.2% from 22.4% in the prior year. Net profit after tax (PAT) saw a significant increase of 96% to INR84.8 crores, translating to an EPS of INR5.08. This strong performance was achieved despite a slight sequential drop in USD revenues due to tactical measures to shed lower-margin businesses.

    02

    Strategic Acquisitions and Manufacturing Footprint Expansion

    The company successfully integrated the Arinna acquisition, which closed in April 2026, contributing approximately INR12 crores to Q1 revenue. Additionally, Rubicon acquired a manufacturing site in New Jersey, USA, for USD2.9 million, strategically enhancing its onshore presence and access to government/VA business. Both the Pithampur and New Jersey facilities underwent successful FDA inspections, with commercial operations at Pithampur slated to ramp up from Q1 CY27 and New Jersey expected to commence in CY27 after quality system implementation.

    03

    R&D Investment and Productivity

    Rubicon Research maintained a strong focus on R&D, with expenses totaling INR58 crores, representing 10.9% of consolidated operating revenue for Q1 FY27. The company's R&D productivity, measured as incremental revenue to lagging R&D spend, currently stands at approximately 5.5x, with expectations for further expansion. Management reiterated its guidance to spend INR500 crores on R&D over nine quarters (FY26, FY27, Q1 FY28) and confirmed being on track to meet this target by Q1 FY28.

    04

    Upward Revision of FY27 EBITDA Guidance

    Despite anticipated cost impacts from new ESOP schemes, Arinna growth initiatives, and pre-revenue costs for new facilities in New Jersey and Pithampura, management expressed confidence in revising its full-year FY27 EBITDA guidance upwards. The earlier guidance of 22-23% is now expected to be exceeded, reflecting strong operational leverage and the benefits of a strategic portfolio mix. This revision underscores management's positive outlook on sustained profitability.

    05

    Organizational Restructuring for Future Growth

    In a significant organizational update, Mr. Nitin Jajodia, the current Chief Financial Officer, will transition to the role of Chief Commercial Officer. Mr. Rohit will join as the CFO designate and subsequently assume the CFO role. This strategic move aims to leverage Mr. Jajodia's extensive experience in business functions and enhance management bandwidth to support the company's ambitious growth trajectory and expansion into new areas.

    06

    Cash Flow and Working Capital Management

    The company reported an operating cash flow before working capital changes of INR139 crores, with net cash flow from operating activities at INR28.5 crores. This was impacted by delays in GST refunds, which are expected to normalize📎 in Q2 FY27, leading to healthier cash flow. Net working capital days improved to 114 days as of June 30, 2026, from 126 days on March 31, 2026, though management expects the range to typically be 125-130 days.

    07

    Portfolio Strategy and Margin Enhancement

    Rubicon's portfolio continues to be broad-based, with the top 5 products contributing 39% and top 10 products contributing 55% of Q1 revenue, consistent with prior quarters. The company's focus on specialty and differentiated products has led to stable pricing and a 36% contribution from the specialty portfolio to gross profit. Tactical measures, including shedding lower-margin businesses, have contributed to a sequential gross margin increase of approximately 140 basis points to 67.7%.

    This is an AI-generated summary of a publicly available earnings call transcript.